摘要
原发性肝癌是我国常见的恶性肿瘤,其发病隐袭,进展迅速,发现时多数已失去手术机会,因此预后极差。对于晚期肝癌,索拉非尼是唯一有生存获益的分子靶向药物,该药自2007年上市以来,引起了肝癌分子靶向药物的研究热潮,但遗憾的是,此后未再有新的药物批准用于临床。本文就分子靶向药物在肝癌领域临床研究的相关热点问题作一综述。
Primary liver carcinoma is one of the most common malignancies in China, which is marked by its insidious onset and rapid progression. Most of the cases are unresectable when detected, making the prognosis extremely poor. As the one and only mo-lecular-targeted drug which can bring about survival benefit for advanced hepatocellular carcinoma, sorafenib has aroused a mass re-search fervor of molecular-targeted drugs since 2007, the year it appeared on the market. Regrettably, no new drugs are available for clinical use. This review focuses on central questions regarding molecular-targeted drugs in clinical study for hepatocellular carcinoma.
出处
《临床肿瘤学杂志》
CAS
2016年第5期462-468,共7页
Chinese Clinical Oncology
基金
南京军区医学科技创新基金资助项目(09Z012)
关键词
原发性肝癌
肝细胞癌
抗血管生成治疗
免疫靶向治疗
Primary liver cancer
Hepatocellular carcinoma
Anti-angiogenesis treatment
Targeting immunotherapy
